- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02667106
Phase I Pharmacokinetic Study of RX0041-2
January 25, 2016 updated by: Pharmaceutical Project Solutions, Inc.
Systemic Pharmacokinetics of Acute, Topical, Intranasal Administration of RX0041-002 in Healthy Male and Female Subjects
This Phase I study is to examine the systemic pharmacokinetics of RX0041-002 following acute, topical, intranasal administration to healthy male and female volunteers.
Study Overview
Detailed Description
This is a Phase I, single dose, single-center, open-label study of the plasma and urinary pharmacokinetics of RX004-002 and its major metabolites in male and female healthy subjects.
Study Type
Interventional
Enrollment (Actual)
30
Phase
- Phase 1
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Male or female ≥18 but ≤ 80 years of age at the time of dosing.
- BMI ≥ 18 and ≤ 32 at the screening visit.
- Females (if of child-bearing potential and sexually active) and males (if sexually active with a partner of child-bearing potential) who agree to use a medically acceptable and effective birth control method from the first dose and for 8 days following administration of study drug. Medically acceptable methods of contraception that may be used by the participant and/or his/her partner include abstinence, birth control pills or patches, diaphragm, intrauterine device (IUD), condom, surgical sterilization, and progestin implant or injection. Prohibited methods include: the rhythm method or withdrawal.
- Willing and able to provide written informed consent and able to understand and comply with protocol requirements.
- During the period of study confinement, subjects will be required to abstain from beverages containing grapefruit juice or caffeine.
Exclusion Criteria:
- Has a known allergy to any ester based anesthetics including cocaine HCl, procaine, tetracaine, chloroprocaine, dibucaine, or benzocaine Amide based anesthetic allergies are NOT exclusionary. Amide based anesthetics are: Lidocaine, mepivicaine, bupivicaine, levobupivicaine, ropivicaine, etidocaine, prilocaine, and articaine.
- The use of amphetamines, methylphenidate or other stimulant prescription and nonprescription products such as pseudoephedrine, bronchial inhalers containing sympathomimetics (epinephrine or other beta-receptor agonist) or herbal products in the 7 days prior to screening or has a need to use these drugs during the course of the study.
- Use of any SNRIs/SSRIs antidepressants or tricyclic antidepressant up to7 days or 5 half-lives (whichever is longer) prior to screening or has a need to use these drugs during the screening period and throughout the time period of the trial.
- Use of MAO Inhibitor drugs up to14 days prior to screening or has a need to use these drugs during the screening period and throughout the time period of the trial.
- Has a history of abuse of controlled substances, nasal or otherwise, or has damage to the nasal space, that in the opinion of the investigator might interfere with the ability to absorb RX0041-002.
- Has severely traumatized mucosa or sepsis in the nasal cavity.
- Has participated in an investigational study or received an investigational drug within 30 days preceding the randomization.
- Is a pregnant or nursing mother.
- Has a positive pregnancy test at Screening or Day 1.
- Has a history of seizure, with the exception of febrile seizures.
- Has glaucoma, symptomatic cardiovascular disease, or moderate to severe hypertension (defined as an average SBP ≥160 mmHg or an average DBP ≥ 100 mmHg at the dosing visit).
- Has a known personal or family history of hereditary pseudocholinesterase deficiency. Study participants will be screened by asking about personal or family history of anesthetic reaction, anesthetic death, and previous diagnosis of psuedocholinesterase deficiency in a relative or personally. Subjects identified with pseudocholinesterase deficiency are at risk for delayed recovery with certain anesthetics (e.g. succinylcholine and ester-based anesthetics).
- Has a known personal or family history of pheochromocytoma. Study participants will be specifically asked if they have been treated for a pheochromocytoma previously or if they have a family member who has been diagnosed with pheochromocytoma (since 10% of these are familial).
- Has a known personal or family history of adrenal tumor.
- ECG abnormalities judged clinically significant by the investigator.
- Has a positive urine test result for drugs of abuse (amphetamines, barbiturates, cannabinoids, cocaine metabolites, opiates and oxycodone) at Screening or Day 1
- Hematocrit, WBC, or platelets outside the normal limits and judged clinically significant by the investigator.
- Serum potassium outside normal limits and judged clinically significant by the investigator.
- Serum ALT, AST, and bilirubin exceeding 2X ULN for the lab's reference values.
- Evidence of impaired renal function based upon laboratory tests and investigator opinion.
- Clinical chemistry abnormalities judged clinically significant by the investigator.
- Donation of blood (one pint or greater) within four weeks prior to administration of study medication.
- Not suitable for entry into the study in the opinion of the investigator.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Basic Science
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Single-dose, open label RX0041-2
Active Drug
|
Pharmacokinetic study
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Pharmacokinetic Measurement of RX0041
Time Frame: 24 Hours
|
Cmax of RX0041
|
24 Hours
|
Pharmacokinetic Measurement of RX0041
Time Frame: 24 Hours
|
AUC of RX0041
|
24 Hours
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Investigators
- Study Director: Melissa L Goodhead, MSc, Clinical/Regulatory Agent
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
October 1, 2015
Primary Completion (Actual)
October 1, 2015
Study Completion (Actual)
October 1, 2015
Study Registration Dates
First Submitted
January 18, 2016
First Submitted That Met QC Criteria
January 25, 2016
First Posted (Estimate)
January 28, 2016
Study Record Updates
Last Update Posted (Estimate)
January 28, 2016
Last Update Submitted That Met QC Criteria
January 25, 2016
Last Verified
January 1, 2016
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 2015016
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Undecided
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Drug Reaction to Analgesic Nos
-
Pharmaceutical Project Solutions, Inc.Completed
-
Tigenix S.A.U.CompletedLocalized Adverse Reaction to Administration of DrugSpain
-
Albany Medical CollegeRecruitingAnalgesic Adverse ReactionUnited States
-
St. Louis UniversityCompletedAdverse Reaction to Drug | Allergic Reaction to Contrast MediaUnited States
-
Rigshospitalet, DenmarkUnknownAnalgesic Adverse Reaction | Gonad Regulating Hormone Adverse ReactionDenmark
-
Second Hospital of Shanxi Medical UniversityRecruitingOpioid Analgesic Adverse ReactionChina
-
Gregory A. DekabanUniversity of Western Ontario, Canada; Ontario Institute for Cancer ResearchUnknownAdverse Reaction to Diagnostic Agents and Kits NosCanada
-
University Hospital, AkershusCompletedCesarean Delivery Affecting Newborn | Analgesic Adverse ReactionNorway
-
Chulalongkorn UniversityUnknownDrug ReactionThailand
-
Beijing Center for Disease Control and PreventionUnknown
Clinical Trials on RX0041-2
-
Pharmaceutical Project Solutions, Inc.Cognitive Research CorporationCompletedAnalgesic AllergyUnited States
-
Pharmaceutical Project Solutions, Inc.Cognitive Research CorporationCompleted
-
Pharmaceutical Project Solutions, Inc.Completed
-
University College, LondonMoorfields Eye Hospital NHS Foundation Trust; Targeted Genetics CorporationCompletedRetinal DegenerationUnited Kingdom
-
Yuhan CorporationCompletedRheumatic ArthritisKorea, Republic of
-
Medifast, Inc.Completed
-
University of South CarolinaTerminatedSedentary Lifestyle | Knee Osteoarthritis | Knee Injuries | Knee Pain ChronicUnited States
-
University of PennsylvaniaNational Cancer Institute (NCI); PfizerCompleted
-
Metabolic Technologies Inc.National Institute on Aging (NIA); Vanderbilt UniversityCompleted
-
University of Sao Paulo General HospitalCompletedOveractive Bladder SyndromeBrazil